Article PDF first page preview

First page of International consensus on the diagnosis and management of endocrine complications of β and α thalassemia in children and adolescents

β-thalassemia (βT) and α-thalassemia (αT) are chronic hemolytic anemias caused by hereditary defects in the β or α chains of hemoglobin respectively. According to the clinical picture, both forms of thalassemia are subdivided into minor, intermedia or major. Previous guidelines focused on growth and endocrine dysfunctions in βT major, where the complications reported are consequences of iron toxicity. However emerging evidence shows that patients with other forms of thalassemia are also at risk of some endocrinopathies. This guideline provides consensus on the screening and management of endocrine complications of children and adolescents with different forms of thalassemia. The panel has 14 experts from 13 countries representing 8 societies. They reviewed literature up to 2024 for the highest available evidence on the subject and 42 recommendations were modified until at least 70% vote for agreement was achieved. Hypogonadism, delayed growth and puberty are common in βT major and transfusion dependent (TD) αT HbH disease and they are also reported in βT intermedia and non-TD αT HbH disease. Osteopenia, adrenal insufficiency and reproductive dysfunction are reported only in βT major and TD αT HbH disease. In addition, hypothyroidism, diabetes and hypoparathyroidism are also reported in TD and non-TD thalassemia. Adherence to modern transfusion, and iron chelation can prevent or reverse endocrine complications. Regular screening should be conducted before the age of 10 years in patients with TD thalassemia, and from 11 years onwards in non-TD thalassemia. Those who received hematopoietic stem cell transplantation for βT major are at risk of endocrinopathies and should be managed similarly to individuals with TD thalassemia.

Journal Section:
Clinical Practice Committee Publication
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.